JNJ · Johnson & Johnson
AI read · Neutral
The AI's read
The profit beat and higher company forecast point to stronger results this year. The MedTech sales miss and expected 2027 profit cut point the other way, so neither side clearly leads.
J&J is having its toughest day since April 2025 because its MedTech sales fell short.
Neutral
Johnson & Johnson beat profit estimates and raised its full-year forecast, but MedTech sales missed and drug deals will cut 2027 adjusted profit by $1.36 per share. The good news and costs point in different directions.
XLV · State Street Health Care Select Sector SPDR ETF
AI read · Neutral
The connection
Johnson & Johnson is the fund's second-largest holding, but this report mixes stronger company results with weak device sales and future deal costs. It does not show a clear change for the fund.
Get alerts for JNJ
Follow Johnson & Johnson (JNJ) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for JNJFree on the App Store and Google Play, or on the web.